Biomerica Inc (BMRA)vsBoston Scientific Corp (BSX)
BMRA
Biomerica Inc
$2.12
-1.17%
HEALTHCARE · Cap: $5.96M
BSX
Boston Scientific Corp
$48.55
+0.76%
HEALTHCARE · Cap: $69.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 476304% more annual revenue ($20.61B vs $4.33M). BSX leads profitability with a 17.3% profit margin vs -96.5%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BMRA
Avoid26
out of 100
Grade: F
BSX
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BMRA.
Margin of Safety
-25.6%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -125.8% — below average capital efficiency
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRA
The strongest argument for BMRA centers on Debt/Equity, Price/Book.
Bull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : BMRA
The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Key Dynamics to Monitor
BMRA profiles as a turnaround stock while BSX is a mature play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.56 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 26/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomerica Inc
HEALTHCARE · MEDICAL DEVICES · USA
Biomerica Inc. (Ticker: BMRA) is a forward-thinking biotechnology firm dedicated to developing and manufacturing advanced diagnostic solutions across medical and food industries. The company focuses on proprietary testing methods targeting metabolic diseases, gastrointestinal disorders, and food intolerances, aiming to enhance healthcare outcomes and diagnostics accuracy. By engaging in strategic research collaborations and leveraging innovative technologies, Biomerica is strategically positioned to address significant unmet medical needs while capitalizing on growth opportunities within the dynamic diagnostics market. Its commitment to a patient-centric approach underscores its potential to drive transformative changes in global healthcare diagnostics.
Visit Website →Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?